UNLABELLED: Aristolochic acid I (AAI) is a natural plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. One of the most efficient enzymes reductively activating AAI to species forming AAI-DNA adducts is cytosolic NAD(P)H: quinone oxidoreductase 1. AAI is also either reductively activated or oxidatively detoxified to 8-hydroxyaristolochic acid (AAIa) by microsomal cytochrome P450 (CYP) 1A1 and 1A2. Here, we investigated which of these two opposing CYP1A1/2-catalyzed reactions prevails in AAI metabolism in vivo. The formation of AAI-DNA adducts was analyzed in liver, kidney and lung of rats treated with AAI, Sudan I, a potent inducer of CYP1A1/2, or AAI after pretreatment with Sudan I. Compared to rats treated with AAI alone, levels of AAI-DNA adducts determined by the (32)P-postlabeling method were lower in liver, kidney and lung of rats treated with AAI after Sudan I. The induction of CYP1A1/2 by Sudan I increased AAI detoxification to its O-demethylated metabolite AAIa, thereby reducing the actual amount of AAI available for reductive activation. This subsequently resulted in lower AAI-DNA adduct levels in the rat in vivo. Our results demonstrate that CYP1A1/2-mediated oxidative detoxification of AAI is the predominant role of these enzymes in rats in vivo, thereby suppressing levels of AAI-DNA adducts.

Analytical and Environmental Sciences Division MRC PHE Centre for Environment and Health King's College London London United Kingdom

Department of Biochemistry Faculty of Science Charles University Prague Prague Czech Republic

Division of Radiopharmaceutical Chemistry German Cancer Research Center Heidelberg Germany

German Cancer Consortium Heidelberg Germany

000      

00000naa a2200000 a 4500

001      

bmc16027696

003      

CZ-PrNML

005      

20171215201518.0

007      

ta

008      

161005s2016 ie f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.tox.2016.01.011 $2 doi

024    7_

$a 10.1016/j.tox.2016.01.011 $2 doi

035    __

$a (PubMed)26845733

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ie

100    1_

$a Dračínská, Helena $u Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic.

245    10

$a Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo / $c H. Dračínská, F. Bárta, K. Levová, A. Hudecová, M. Moserová, HH. Schmeiser, K. Kopka, E. Frei, VM. Arlt, M. Stiborová,

520    9_

$a UNLABELLED: Aristolochic acid I (AAI) is a natural plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. One of the most efficient enzymes reductively activating AAI to species forming AAI-DNA adducts is cytosolic NAD(P)H: quinone oxidoreductase 1. AAI is also either reductively activated or oxidatively detoxified to 8-hydroxyaristolochic acid (AAIa) by microsomal cytochrome P450 (CYP) 1A1 and 1A2. Here, we investigated which of these two opposing CYP1A1/2-catalyzed reactions prevails in AAI metabolism in vivo. The formation of AAI-DNA adducts was analyzed in liver, kidney and lung of rats treated with AAI, Sudan I, a potent inducer of CYP1A1/2, or AAI after pretreatment with Sudan I. Compared to rats treated with AAI alone, levels of AAI-DNA adducts determined by the (32)P-postlabeling method were lower in liver, kidney and lung of rats treated with AAI after Sudan I. The induction of CYP1A1/2 by Sudan I increased AAI detoxification to its O-demethylated metabolite AAIa, thereby reducing the actual amount of AAI available for reductive activation. This subsequently resulted in lower AAI-DNA adduct levels in the rat in vivo. Our results demonstrate that CYP1A1/2-mediated oxidative detoxification of AAI is the predominant role of these enzymes in rats in vivo, thereby suppressing levels of AAI-DNA adducts.

650    _2

$a zvířata $7 D000818

650    _2

$a kyseliny aristolochové $x toxicita $7 D034341

650    _2

$a karcinogeny $x toxicita $7 D002273

650    _2

$a cytochrom P-450 CYP1A1 $x biosyntéza $7 D019363

650    _2

$a cytochrom P-450 CYP1A2 $x biosyntéza $7 D019388

650    _2

$a adukty DNA $x antagonisté a inhibitory $x biosyntéza $7 D018736

650    _2

$a enzymová indukce $x účinky léků $x fyziologie $7 D004790

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a potkani Wistar $7 D017208

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Bárta, František $u Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Levová, Kateřina $u Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Hudecová, Alena $u Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Moserová, Michaela $u Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Schmeiser, Heinz H $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany.

700    1_

$a Kopka, Klaus $u Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.

700    1_

$a Frei, Eva $u Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Arlt, Volker M. $u Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment & Health, King's College London, London, United Kingdom. $7 xx0074763 $4

700    1_

$a Stiborová, Marie $u Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic. Electronic address: stiborov@natur.cuni.cz.

773    0_

$w MED00004533 $t Toxicology $x 1879-3185 $g Roč. 344-346, č. - (2016), s. 7-18

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26845733 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20161005 $b ABA008

991    __

$a 20161031102149 $b ABA008

999    __

$a ok $b bmc $g 1166010 $s 952326

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2016 $b 344-346 $c - $d 7-18 $e 20160201 $i 1879-3185 $m Toxicology $n Toxicology $x MED00004533

LZP    __

$a Pubmed-20161005